Objective: Based on a common mechanism of action with gabapentin, we investigated the effects of L-methionine on hot flashes in postmenopausal women.
G abapentin has been shown in several randomized controlled trials (RCTs) to be an effective nonhormonal treatment for hot flashes. 1Y4 It has been theorized that gabapentin's mechanism of action in treating hot flashes stems from decreasing neuronal calcium currents 5, 6 via interaction with its central nervous system and peripheral nervous system binding site, the > 2 C subunit of voltage-gated calcium channels. 6 Several large neutral amino acids also have an affinity for this binding site that is comparable to that of gabapentin. Of the amino acids that are classified as dietary supplements, L-methionine and L-isoleucine have the first-and second-highest affinities in mouse cerebral cortex, respectively, with L-methionine's affinity equal to gabapentin's and approximately 40% higher than L-isoleucine's. 7 We initially studied the effects of L-isoleucine on hot flashes because, at that time, elevated serum homocysteine was felt to be a risk factor for cardiovascular disease, 8 and L-methionine therapy was known to elevate serum homocysteine. 9, 10 In that RCT, we showed that L-isoleucine was ineffective in the treatment of hot flashes. 11 After the initiation of the isoleucine hot flash RCT, two large RCTs were published, 12, 13 and one was presented at the American Heart Association 2006 Scientific Sessions and recently published, 14 all showing that lowering serum homocysteine by 18% to 27% through the use of B-vitamin therapy led to no cardiovascular benefit. These three RCTs in addition to one previously published RCT 15 cumulatively enrolled more than 18,000 participants and cast significant doubt on a causative role of homocysteine in cardiovascular disease. This encouraged us to revisit L-methionine therapy in the treatment of hot flashes because it has the same affinity as gabapentin for the proposed therapeutic target. 7 We conducted a two-phase RCT in postmenopausal women to investigate whether L-methionine was effective in the treatment of hot flashes at a dose of 2 g/day (phase 1) and 4 g/day (phase 2).
METHODS

Participants
Participants were recruited from a TV segment on a local news channel and from newspaper advertisements. We screened 378 callers and enrolled 51 eligible participants; the main three reasons for ineligibility were inadequate frequency of hot flashes, disinterest in the study, and perimenopausal state. Eligible participants could not report having any menses for at least 12 months or report having a bilateral oophorectomy more than 6 weeks previously and have baseline serum follicle-stimulating hormone greater than 40 mIU/mL; could not have taken any form of prescription estrogen or progesterone for at least 2 months; could not have had any change in exposure to an antidepressant, a selective estrogen receptor modulator (such as raloxifene or tamoxifen), an aromatase inhibitor (such as anastrozole, letrozole, or exemestane), leuprolide acetate, clonidine, or an over-the-counter hot flash treatment for at least 1 month; and could not have had any exposure to an amino acid supplement, gabapentin, or pregabalin for at least 1 month. Eligible participants needed to be experiencing at least five moderate-severe hot flashes per day for at least 2 months; moderate and severe hot flashes needed to have perspiration associated with the hot flash. The study was approved by the institutional review board at the University at Buffalo, and all participants provided written informed consent to participate.
Randomization and study medication
This was a single-site study conducted at the University at Buffalo's Student Health Center. Fifty-one women were enrolled between January and May 2007. After a 1-week baseline period, participants were randomized to one of three groups (phase 1/phase 2) in a 13:13:25 ratio: placebo/placebo, placebo/L-methionine, or L-methionine/L-methionine, respectively. The computer-generated randomization plan was available only to the programmer at the University of Rochester who generated the plan and the pharmacist at the University at Buffalo who packaged the drug; no other study personnel had access to this plan. Phase 1 was 12 weeks long, and phase 2 was 8 weeks long. We were primarily interested in data from phase 1; therefore, a 12-week treatment duration was used as recommended by the Food and Drug Administration's Guidance for Industry. 16 We chose an 8-week treatment period for phase 2 because the data from this phase were of secondary interest, and it seems that 8 weeks is the minimal treatment period necessary for demonstrating long-term efficacy of a nonhormonal compound. For example, three separate nonhormonal compounds have shown efficacy in hot flash RCTs at early time points (2, 6, and 7 wk, respectively) only to subsequently lose efficacy at later time points. 17Y19 Participants took 1 g PO BID in phase 1 and 2 g PO BID in phase 2 of either L-methionine or identically appearing placebo capsules containing corn starch and methylcellulose.
All participants also took folate 1 mg and methylcobalamin 0.5 mg a day (Vitacost, Inc.; vitacost.com) to help minimize the L-methionineYinduced elevation in serum homocysteine. The exact identity of the amino acid used in the study was not revealed to the participants until after the study to help prevent them from purchasing L-methionine over the counter and taking it during the study.
Evaluations
Participants completed daily hot flash diaries for a 1-week period before randomization and for the full 20 weeks of both phases 1 and 2 of the study. Participants were instructed to keep the diary with them and record each hot flash after it occurred as mild, moderate, or severe. 16 Night sweats were also recorded. Participants mailed each completed diary directly to the General Clinical Research Center at the University of Rochester, Rochester, NY. The following questionnaires were also completed at baseline, week 12, and week 20: The Pittsburgh Sleep Quality Index, 20 The Greene Climacteric Scale, 21 and the Hot Flash Bother Scale (HFBS), which asked participants to rate on two 10-point Likert scales ranging from 1 (not bothered at all) to 10 (extremely bothered) how much they had been bothered recently by their daytime hot flashes and nighttime hot flashes/night sweats, respectively. Global satisfaction with treatment was assessed at weeks 12 and 20 using a numerical scale ranging from 1 (extremely dissatisfied) to 10 (extremely satisfied). Laboratory tests were assayed in the fasting state (no food or study capsules for at least 8 h) between 8 and 10 AM, and weight was also assessed at randomization and at weeks 12 and 20. Blood samples to be assayed for homocysteine were immediately placed in a 4-C refrigerator and centrifuged within 1 hour of the draw. The serum was then immediately poured into a separate tube, and homocysteine was assayed the same day. Laboratory testing was performed at Kaleida Health Laboratories, Buffalo, NY, and at Strong Memorial Hospital, Rochester, NY. Adverse events were assessed by the principal investigator at each participant visit, by inquiry.
Statistical analysis
The primary outcome measure was percent change in hot flash composite score from baseline to week 12 as determined by participants' daily hot flash diaries. The hot flash composite score combines frequency and severity into one score by assigning the numbers 1, 2, and 3 to mild, moderate, and severe hot flashes, respectively, and then summing across all hot flashes. Secondary outcome variables included percent change in hot flash frequency (number of hot flashes per day) from baseline to week 12, changes from baseline to week 12 in the Pittsburgh Sleep Quality Index global score, Greene Climacteric Scale total score, HFBS score, fasting serum homocysteine level, weight, laboratory test results, and global satisfaction with treatment at week 12. Changes from baseline to week 20 were also considered in the statistical analyses.
For phase 1, the statistical analyses were performed according to the intention-to-treat principle and included data from all randomized participants. The hot flash diary outcomes were analyzed using a repeated-measures analysis of variance model that included terms for treatment group (L-methionine, placebo), week (categorical), and the interaction between treatment group and week. This allowed estimation of the treatment effects separately for each week (including the primary time point at week 12) along with associated 95% CIs. All available data from all randomized participants were included in these analyses, with maximal likelihood used to estimate the model parameters of interest in the setting of missing data. 22 Changes from baseline to week 12 in the other outcome variables were compared between the L-methionine and placebo groups using Wilcoxon rank sum tests, with missing data at week 12 imputed with the last available observation. Treatment effects were estimated using the Hodges-Lehmann estimates of the group differences in population medians and their associated 95% CIs. 23 For phase 2, the hot flash diary outcomes were analyzed as in phase 1 (repeated-measures analysis of variance), with a focus on estimating treatment effects at week 20. The significance of group differences in mean changes from baseline to week 20 in the other clinical and laboratory outcomes was examined using Wilcoxon rank sum tests, with a focus on the comparison between the L-methionine/L-methionine group (n = 25) and the placebo/placebo group (n = 13). The statistical analyses for these outcome variables in phase 2 were exploratory and did not use imputation for missing data.
A comparison of the means between the daytime and nighttime HFBS scores among the 51 participants at baseline was performed using a paired t test.
The sample size of 51 participants was chosen to provide 80% power to detect a group difference (L-methionine j placebo) in mean response of 30% for the primary outcome variable of percent change from baseline to week 12 in hot flash composite score, using a t test and a two-tailed significance level of 5%. The chosen effect size of 30% was based on that observed using doses of gabapentin similar to the L-methionine dose used here 2 and the fact that L-methionine and gabapentin have the same affinity for the proposed therapeutic target. 7 The calculation also assumed an SD of 37.5% for the primary outcome variable based on the results from the L-isoleucine hot flash trial. 11 All statistical analyses were performed through the General Clinical Research Center at the University of Rochester.
RESULTS
The baseline characteristics are summarized in Table 1 by treatment received in phase 1. The L-methionine and placebo groups were generally comparable, with the L-methionine group having a slightly higher hot flash frequency at baseline. Four participants withdrew from phase 1 of the study (three L-methionine participants for nausea, lack of benefit, and loss-to-follow-up and one placebo participant for worsening hot flashes). Five participants withdrew from phase 2 of the study, all of whom were taking L-methionine in phase 2 (three for worsening hot flashes and two were lost to followup; Fig. 1 ).
In phase 1 of the study, there were no significant differences between the L-methionine and placebo groups for any of the hot flash or clinical outcome variables ( Fig. 2 and Table 2 ). For the hot flash composite score, the mean percent changes from baseline to week 12 (estimated from the repeated-measures analysis of variance model) were j37.4% in the L-methionine group and j33.4% in the placebo group (P = 0.60). There were significant increases in fasting serum homocysteine and L-methionine levels (1.7 and 13.9 Kmol/L, respectively) associated with 2 g/day of L-methionine relative to placebo.
In phase 2 of the study, there were again no significant changes in any of the hot flash outcomes associated with double-dose (4 g/d) L-methionine therapy as compared with placebo ( Table 3 ). Fasting serum homocysteine and Lmethionine levels showed large increases after 8 weeks of L-methionine 4 g/day (Table 3) . 1.0 j1.0 to 3.0 0.49 PSQI, Pittsburgh Sleep Quality Index; GCS, Greene Climacteric Scale; FSH, follicle-stimulating hormone; LH, luteinizing hormone. a Values are presented as mean (SD) change from baseline to week 12 except for global satisfaction with treatment, for which the mean score at week 12 is presented. b Treatment effect is estimated from a repeated-measures analysis of variance model for the hot flash diary outcomes and is the Hodges-Lehmann estimate of the group difference (L-methionineYplacebo) in population medians for the other outcome variables; see text for details. At baseline, the 51 participating women reported being more bothered by their nighttime hot flashes/night sweats than by their daytime hot flashes according to the HFBS scores measured on the 10-point Likert scale (mean nighttime j daytime difference = j0.84; 95% CI, j1.54 to j0.15; P = 0.02).
DISCUSSION
This study demonstrated that L-methionine is ineffective in the treatment of hot flashes in postmenopausal women. This lack of efficacy was apparently not due to inadequate intestinal absorption of L-methionine as serum levels of L-methionine, and homocysteine rose significantly at both 2 and 4 g of Lmethionine a day. We hypothesized that these doses of Lmethionine would be effective in the treatment of hot flashes because L-methionine has the same affinity for the theoretical hot flash therapeutic target as does gabapentin, 9 and gabapentin has repeatedly been shown to be an effective hot flash treatment even at much lower doses. 1Y4 L-Methionine may not have the same physiological effects at this binding site as does gabapentin.
The compound pregabalin is closely related structurally and functionally to gabapentin 24 and is currently being studied in an RCT to determine its effectiveness in the treatment of hot flashes. 25 Positive results from the pregabalin trial would help to validate the > 2 C subunit of voltage-gated calcium channels as a therapeutic target in the treatment of hot flashes.
In this study, the two doses of L-methionine were associated with 16% and 61% increases in homocysteine, respectively, compared with baseline. Observational studies have linked elevated homocysteine with increased risk for cardiovascular disease; however, RCTs have repeatedly failed to show any cardiovascular benefit associated with lowering homocysteine by 18% to 27% through the use of B-vitamin therapy. Based on these data, elevated homocysteine is more likely to represent a biomarker for cardiovascular risk rather than a causative agent itself. It is unclear if the L-methionineY induced elevations in homocysteine in this study are clinically significant.
It is not surprising that women at baseline reported being more bothered by their nighttime hot flashes/night sweats than their daytime hot flashes because night sweats frequently interfere with sleep. Sleep disruption is commonly associated with the menopausal transition, and the presence of chronic insomnia is positively associated with the severity of hot flashes. 26 CONCLUSIONS L-Methionine therapy seems to be ineffective in the treatment of hot flashes in postmenopausal women.
